Source: Novocell, Inc.
Posted: October 19, 2006 3:05 pm ET
Summary:
Novocell, Inc., a stem cell engineering company, announced the development of a process that efficiently converts human embryonic stem cells into insulin-producing pancreatic endocrine cells. The findings are reported in an article appearing on-line today, in advance of print publication, in the journal Nature Biotechnology. Such an approach could provide a means to produce sufficient quantities of insulin producing cells for transplantation into patients with Type 1 diabetes, a treatment that offers a potential therapy for this disease.
Commentary: Hopefully this finding will eventually enable pancreatic endocrine cells to be safely transplanted into patients with type 1 diabetes without risks or harmful side effects.
No comments:
Post a Comment